Conference Details - Overview
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Current Trends in Leukemia, Lymphoma, and Myeloma
The Westin Galleria Dallas
Dallas, TX
January 10, 2009
Conference Overview
Oncology CME-Certified Regional Meeting
Current Trends in Leukemia, Lymphoma, and Myeloma is a symposium designed to update practicing medical oncologists, hematologists, and nurses on data on the treatment and management of leukemia, lymphoma, and myeloma presented at major national hematology conferences in 2008. Novel agents for the treatment of hematologic malignancies and recent developments in supportive therapy will also be discussed. These advances will be addressed through presentations by key thought leaders, interactive case discussions, and question-and-answer opportunities. The overall objective of the symposium is to provide updates on treatment options that can be integrated into the treatment of patients with various hematologic malignancies as well as enhance awareness of novel agents that are in development in order to increase the number of patients enrolled in clinical trials.
This educational program is directed toward medical oncologists and hematologists interested in the treatment of hematologic malignancies. Physician assistants, nurses, fellows, pharmacists, and others interested in the treatment of cancer are also invited to attend.At the conclusion of this symposium, you should be able to:
- Compare the different emerging treatment options for patients with idiopathic thrombocytopenic purpura
- Evaluate current treatment options for the management of aggressive non-Hodgkin lymphoma, including the use of monoclonal antibodies to improve survival
- Compare treatment options for newly diagnosed and relapsed/refractory multiple myeloma, including regimens containing immunomodulatory agents and proteasome inhibitors
- Describe recent advances in the management of mantle cell and T-cell lymphomas with monoclonal antibodies, histone deacetylase inhibitors, and proteasome inhibitors
- Assess the role of monoclonal antibodies in the treatment of low-grade non-Hodgkin lymphoma, including their potential in improving clinical outcomes
- Evaluate the potential of emerging novel agents to improve response in patients with relapsed/refractory non-Hodgkin lymphoma
- Discuss next-generation tyrosine kinase inhibitors and other novel agents in the management of patients with chronic myeloid leukemia who develop resistance to initial therapy
- Describe emerging agents in the treatment of multiple myeloma, including novel proteasome inhibitors and novel formulations of anthracyclines
- Analyze the safety and efficacy of immunomodulatory and hypomethylating agents, growth factors, and novel agents in the optimal management of myelodysplastic syndromes
- Integrate novel treatment regimens into the management of chronic lymphocytic leukemia, including monoclonal antibodies in combination with growth factors, purine analogues, and other targeted agents
- Compare novel agents in the optimal management of acute leukemias, including farnesyltransferase inhibitors, purine nucleoside analogues, and kinase inhibitors
- Implement advances in supportive care for patients with hematologic malignancies, including the prevention of tumor lysis syndrome; mobilization of stem cells for transplantation; and management of iron overload, anemia, and neutropenia
Educational Grants
An educational grant for this activity was provided by:
- GlaxoSmithKline
- Celgene Corporation
- Genentech BioOncology/
Biogen Idec - Millennium Pharmaceuticals
- Eisai, Inc.